Search results
Showing 3501 to 3550 of 4090 results for patient
Physical activity: encouraging activity in the community (QS183)
This quality standard covers how local strategy, policy and planning and improvements to the built or natural physical environment such as public open spaces, workplaces and schools can encourage and support people of all ages and all abilities to be physically active and move more. It describes high-quality care in priority areas for improvement.
View quality statements for QS183Show all sections
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Psychosis and schizophrenia in adults: prevention and management (CG178)
This guideline covers recognising and managing psychosis and schizophrenia in adults. It aims to improve care through early recognition and treatment, and by focusing on long-term recovery. It also recommends checking for coexisting health problems and providing support for family members and carers.
NICE publishes first quality standard to improve care for people with rare diseases
Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Inhaled insulin for the treatment of type 1 and type 2 diabetes (TA113)
In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete. Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications. 25 January 2008
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
Optical Coherence Tomography to guide percutaneous coronary intervention
In development Reference number: GID-IPG10394 Expected publication date: TBC
Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]
Discontinued Reference number: GID-TA11256
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
In development Reference number: GID-TA11455 Expected publication date: TBC
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]
Discontinued Reference number: GID-TA11205
Gantenerumab for treating early Alzheimer's disease [ID6142]
In development Reference number: GID-TA11269 Expected publication date: TBC
Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]
Discontinued Reference number: GID-TA11176
Discontinued Reference number: GID-TA11120
Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma
Discontinued Reference number: GID-TA10970
Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]
Discontinued Reference number: GID-TA11238
Discontinued Reference number: GID-TA11207
Masitinib for previously treated moderate Crohn's disease [ID1239]
Discontinued Reference number: GID-TA11188
Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]
Discontinued Reference number: GID-TA11210
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
Discontinued Reference number: GID-TA11206
Discontinued Reference number: GID-TA11119
In development Reference number: GID-TA11689 Expected publication date: TBC
In development Reference number: GID-TA11546 Expected publication date: TBC
In development Reference number: GID-MT594 Expected publication date: TBC
Discontinued Reference number: GID-TA11181
In development Reference number: GID-TA11345 Expected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
In development Reference number: GID-TA11070 Expected publication date: TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia [TSID10726]
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11646 Expected publication date: TBC
Inebilizumab for treating immunoglobulin G4-related disease [ID6600]
In development Reference number: GID-TA11665 Expected publication date: TBC
In development Reference number: GID-TA11880 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued Reference number: GID-TA11522
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]
Discontinued Reference number: GID-TA11712
In development Reference number: GID-TA11457 Expected publication date: TBC
In development Reference number: GID-TA11491 Expected publication date: TBC
In development Reference number: GID-TA11745 Expected publication date: TBC
Discontinued Reference number: GID-TA11179
Discontinued Reference number: GID-MT130
Oral semaglutide for managing overweight and obesity [ID6188]
Discontinued Reference number: GID-TA11149
In development Reference number: GID-TA11406 Expected publication date: TBC
In development Reference number: GID-TA11792 Expected publication date: TBC
Deucravacitinib for treating active psoriatic arthritis [ID6561]
In development Reference number: GID-TA11510 Expected publication date: TBC
In development Reference number: GID-TA11511 Expected publication date: TBC
Non-invasive skin closure devices for surgical incisions (MT775)
In development Reference number: GID-MT593 Expected publication date: TBC